Drugs that target the GLP-1 receptor (GLP-1R), such as liraglutide and losenatide, have garnered significant attention due to their ability to effectively promote insulin secretion and enhancing glucose homeostasis (6, 7); these agents offer promising options for alleviating and treating diabetes mellitus and its associated complications. The gene discussed is INS; the disease is diabetes mellitus.